These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31935761)

  • 1. Home Self-Administration of Biologics - A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians.
    Timmermann H; Mailänder C
    Pneumologie; 2020 Feb; 74(2):103-111. PubMed ID: 31935761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of biologics for the treatment of asthma.
    Pelaia G; Vatrella A; Maselli R
    Nat Rev Drug Discov; 2012 Dec; 11(12):958-72. PubMed ID: 23197041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological agents for severe asthma: the evolution of the at-home self-injection approach.
    Lombardi C; Bagnasco D; Passalacqua G
    Curr Opin Allergy Clin Immunol; 2020 Aug; 20(4):421-427. PubMed ID: 32590510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L; Bardelas J; Viegas A; D'Andrea P; Blogg M; Peachey G
    Curr Med Res Opin; 2014 Jan; 30(1):59-66. PubMed ID: 24028677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.
    Chen H; Eisner MD; Haselkorn T; Trzaskoma B
    Respir Med; 2013 Jan; 107(1):60-7. PubMed ID: 23083840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab as add-on therapy to inhaled steroids for asthma.
    Hadj Tahar A
    Issues Emerg Health Technol; 2004 Jun; (58):1-4. PubMed ID: 15455487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF; Phipatanakul W
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best.
    Papaioannou AI; Fouka E; Papakosta D; Papiris S; Loukides S
    Clin Exp Allergy; 2021 Feb; 51(2):221-227. PubMed ID: 33305478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics for paediatric severe asthma: trick or TREAT?
    Saglani S; Bush A; Carroll W; Cunningham S; Fleming L; Gaillard E; Gupta A; Murray C; Nagakumar P; Paton J; Roberts G; Seddon P; Sinha I
    Lancet Respir Med; 2019 Apr; 7(4):294-296. PubMed ID: 30824361
    [No Abstract]   [Full Text] [Related]  

  • 11. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
    Molimard M; Mala L; Bourdeix I; Le Gros V
    Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.
    Holgate S; Bousquet J; Wenzel S; Fox H; Liu J; Castellsague J
    Curr Med Res Opin; 2001; 17(4):233-40. PubMed ID: 11922396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IgE therapy for asthma: an audit at atertiary care centre in Saudi Arabia.
    Weheba IM; Abdelsayed AM; Arnaout RK; Zeitouni MO; Mobaireek KF; AlHarthi TB; Mobeireek AF
    Ann Saudi Med; 2018; 38(6):439-444. PubMed ID: 30531179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
    Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eligibility for treatment with omalizumab in Italy and Germany.
    Buhl R; Marco AG; Cohen D; Canonica GW
    Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis.
    Cunha FSD; Valle SOR; Elabras Filho J; Dortas Júnior SD; França AT
    J Bras Pneumol; 2018; 44(5):439-441. PubMed ID: 30517345
    [No Abstract]   [Full Text] [Related]  

  • 20. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
    Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.